Human Anti-HLA-A2 PBF Recombinant Antibody (clone D12) (CAT#: FAMAB-0598WJ)
This product is a human monoclonal antibody that is specific for HLA-A2 papillomavirus binding factor (PBF). This antibody can be used in a variety of applications, such as ELISA, WB, FC, Inhib.
Specific Inquiry
Custom Production
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
We require custom production
ELISA
Figure 1 ELISA screening of the specific binders of 94 scFv clones reacting with biotinylated HLA-A*02:01·PBF A2.2 peptide complex.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
FC
Figure 2 FACS analysis of scFv-hIgG1.
T2 cells were pulsed with the indicated peptides and stained with each scFv-hIgG1 at a concentration of 10 μg/ml. BB7.2 was used to detect expression of HLA-A2 molecules.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
SPR
Figure 3 Surface plasmon resonance analysis.
Biotinylated HLA-A*02:01·PBF A2.2 peptide complex (C) or HLA-A*02:01·HIV-A2 peptide complex (D) was immobilized on the sensor tip as the target.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
ELISA
Figure 4 ELISA screening of the reactivity of D12 scFv-hIgG against various biotinylated HLA-A*02:01·peptide complexes.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
FC
Figure 5 FACS analysis of reactivity of D12 scFv-hIgG1 (1 mg/ml) and D12 scFv multimer (10 μg/ml) against T2 cells pulsed with the indicated peptides.
%MFI increase is indicated. T2 without peptide was used as the negative control. A more than 20.0% MFI increase is indicated by underlining.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
FC
Figure 6 FACS analysis of reactivity of D12 scFv-hIgG1 (1 mg/ml) and D12 scFv multimer (10 μg/ml) against T2 cells pulsed with the indicated peptides.
%MFI increase is indicated. T2 without peptide was used as the negative control. A more than 20.0% MFI increase is indicated by underlining.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
FC
Figure 7 FACS analysis of the reactivity of the D12 scFv multimer (3 μg/ml) with sarcoma cell lines and primary culture cells.
Osteosarcoma cell line U2OS (A*02:01/A*3201, PBF+), OS2000 (A*2402, PBF+), KIKU (A*0206/A*2402, PBF+), HOS (A*02:11, PBF+), Saos-2 (A*02:01/A*24:02, PBF+), malignant fibrous histiocytoma cell line MFH2003 (A*2402, PBF−), and primary culture of osteosarcoma (Primary OS; A*02:01, PBF+) were used as target cells. A more than 20.0% MFI increase is indicated by underlining. The expression status of HLA-A2·PBF A2.2 peptide complex was graded as follows: strong (≥100% MFI increase), weak (≥20% but <100% MFI increase), and none (<20% MFI increase).
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
FC
Figure 8 Tetramer staining of oligoclonal CTL line 5A9 directed to HLA-A*02:01·PBF A2.2 peptide before and after positive selection.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
ELISA
Figure 9 CTL response against U2OS cells assessed by ELISA.
Tetramer-positive cells after enrichment were used as the responder.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
Inhib
Figure 10 Inhibition effect of scFv-hIgG1 on CTL response.
scFv D12-hIgG1 and irrelevant scFv D11-hIgG1 were used as blocking antibodies.
Tsukahara, T., Emori, M., Murata, K., Hirano, T., Muroi, N., Kyono, M., ... & Sato, N. (2014). Specific targeting of a naturally presented osteosarcoma antigen, papillomavirus binding factor peptide, using an artificial monoclonal antibody. Journal of Biological Chemistry, 289(32), 22035-22047.
Specifications
- Host Species
- Human
- Derivation
- Phage Display Library
- Type
- Human IgG
- Specificity
- HLA-A2 papillomavirus binding factor (PBF)
- Species Reactivity
- Human
- Clone
- D12
- Applications
- ELISA, WB, FC, Inhib
Product Property
- Purity
- >95% as determined by SDS-PAGE
- Concentration
- Please refer to the vial label for the specific concentration.
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- HLA-A2 PBF
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "HLA-A2 PBF"
Select a product category from the dropdown menu below to view related products.
Please select product type
IgG Antibodies
| CAT | Product Name | Application | Type |
|---|---|---|---|
| FAMAB-0596WJ | Human Anti-HLA-A2 PBF Recombinant Antibody (clone G3) | ELISA, WB, FC, Inhib | Human IgG |
| FAMAB-0597WJ | Human Anti-HLA-A2 PBF Recombinant Antibody (clone H7) | ELISA, WB, FC, Inhib | Human IgG |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for FAMAB-0598WJ. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: WB, ELISA, IP, FC, FuncS, Neut, IF
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: ELISA, IHC
Application: WB, ELISA, FuncS
-2.jpg)
Application: IB, ELISA, FC, FuncS
-YJ5.png)
Application: WB, ELISA, FC, IHC, IP
Application: ELISA, FC, WB, FuncS
Application: WB, ELISA, IF
Application: ELISA, IHC, IF, IP
Application: ELISA, WB
For Research Use Only. Not For Clinical Use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
